Please provide your email address to receive an email when new articles are posted on . The FDA has approved the expanded use area of Klisyri to up to 100 cm 2 on the face and scalp for the treatment ...

Newly published data confirm that daily topical tirbanibulin (Klisyri) was effective at treating actinic keratosis lesions on the face and scalp in two phase III trials. In two identical double-blind ...

The approval was based on data from 2 multicenter, randomized, double-blind, phase 3 trials (ClinicalTrials.gov: NCT03285477 [N=351] and NCT03285490 [N=351]) that compared the efficacy and safety of ...

First-in-class microtubule inhibitor indicated for the topical treatment of actinic keratosis (AK) on the face or scalp with a 5-day application course Klisyri will be manufactured by Athenex Almirall ...

Tirbanibulin ointment 1% shows good safety and tolerability in the treatment of actinic keratosis (AK) in fields of up to 100 cm 2 on the face and scalp. The most common local effects of treatment ...

The randomized, double-blind, placebo-controlled, parallel-cohort Phase 2a clinical trial investigated the efficacy, safety, tolerability, and pharmacokinetics of once-daily application of topical VDA ...

The US Food and Drug Administration has approved a supplemental new drug application for tirbanibulin topical ointment, allowing the expansion of the surface area treated for actinic keratosis (AK) of ...

The approval was based on data from 2 multicenter, randomized, double-blind, phase 3 trials that evaluated the efficacy and safety of Klisyri ointment in adults with AK on the face or scalp. The Food ...

Pharmacology: The mechanism of action by which ingenol mebutate induces cell death in treating actinic keratosis lesions is unknown. Clinical trials: In two double-blind, vehicle-controlled, clinical ...

Woburn, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), and ...

BUFFALO, N.Y., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for ...